The bioSimilia initiative brings the benefits of ultra-minute nano-pharmacological substances to alleviate many disease conditions. Biosimilia is a startup by eminent physician cum researcher Dr Rajesh Shah, MD, who has been working on researching a COVID-19 Nosode called BiosimCovex. We scientifically prepared three variants of COVID-19 Nosode at Mumbai’s Haffkine Institute and Gujarat University. They have undergone pre-clinical and clinical evaluation. Scientific information and research findings of the COVID-19 Nosode are shared on this website.

Phase 1, Phase 2, and Phase 3 studies with BiosimCovex have shown encouraging results. BiosimCovex has demonstrated protection against COVID-19 infection in humans by triggering antibody production — a novel and breakthrough finding.

A proposal for Emergency Approval has been submitted to the Government of India, Ministry of Health and Family Welfare. BiosimCovex is currently under review by various regulatory agencies.